Company CVAbout J B Chemicals & Pharmaceuticals Ltd 
J B Chemicals & Pharmaceuticals Ltd
Small Cap
Pharmaceuticals & Biotechnology
J B Chemicals & Pharmaceuticals Limited (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman.
Company Coordinates
Company Details
Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli Mumbai Maharashtra : 400030
Registrar Details
Datamatics Financial Services Ltd , (Formerly Datamatics Financial Services Ltd) , Plot No A / 16 & A / 17, MIDC, Part B, Cross Lane, Marol , Andheri (E), Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 15.53 Cr
Number of Shares
15.53 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
13-Sep-2024
15.53
15.53
20000
1
Issued under ESOP Scheme
27-Aug-2024
15.53
15.53
69850
1
Issued under ESOP Scheme
08-Aug-2024
15.52
15.52
11500
1
Issued under ESOP Scheme
04-Jun-2024
15.52
15.52
11582
1
Issued under ESOP Scheme
11-May-2024
15.52
15.52
6676
1
Issued under ESOP Scheme
05-Mar-2024
15.52
15.52
43450
1
Issued under ESOP Scheme
05-Feb-2024
15.52
15.52
107190
1
Issued under ESOP Scheme
29-Nov-2023
15.5
15.50
10210
1
Issued under ESOP Scheme
07-Nov-2023
15.5
15.50
78440
1
Issued under ESOP Scheme
18-Sep-2023
15.49
15.49
77464010
1
Stock Split
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 33 Schemes (19.15%)
FIIs
Held by 223 FIIs (15.3%)
Promoter with highest holding
Tau Investment Holdings Pte. Ltd (47.56%)
Highest Public shareholder
Kotak Midcap Fund (4.9%)
Individual Investors Holdings
12.47%
Board of Directors
Management
Designation
Remuneration
Padmini Khare Kaicker
Non-Exec. & Independent Dir.
75.0 lacs
Sumit Bose
Non-Exec. & Independent Dir.
75.0 lacs
Ranjit Shahani.
Chairman & Independent Directo
80.0 lacs
Prashant Kumar.
Non-Exec & Non-Independent Dir
0
Nikhil Chopra
Whole Time Director & CEO
6.54 cr
GAURAV TREHAN
Non-Exec & Non-Independent Dir
0
SANDEEP PHADNIS
Company Sec. & Compli. Officer
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceuticals
1,452.08
96.73%
Other Operating Revenues - Export Incentives
29.25
1.95%
Exchange Rate Difference
10.86
0.72%
Pharmaceuticals
Pharmaceuticals
Other Operating Revenues - Export Incentives
Other Operating Revenues - Export Incentives
Exchange Rate Difference
Exchange Rate Difference
Stock DNARevenue and Profits:
Net Sales:
1,085 Cr
(Quarterly Results - Sep 2025)
Net Profit:
208 Cr
Pharmaceuticals & Biotechnology
INR 28,338 Cr (Small Cap)
40.00
34
0.84%
-0.15
18.88%
7.53
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
